The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota.
Tiziana BisognoAnna LauritanoFabiana PiscitelliPublished in: Life (Basel, Switzerland) (2021)
Alzheimer's disease (AD) is a neurodegenerative disease that progresses from mild cognitive impairment to severe dementia over time. The main clinical hallmarks of the disease (e.g., beta-amyloid plaques and neurofibrillary tangles) begin during preclinical AD when cognitive deficits are not yet apparent. Hence, a more profound understanding of AD pathogenesis is needed to develop new therapeutic strategies. In this context, the endocannabinoid (eCB) system and the gut microbiome are increasingly emerging as important players in maintaining the general homeostasis and the health status of the host. However, their interaction has come to light just recently with gut microbiota regulating the eCB tone at both receptor and enzyme levels in intestinal and adipose tissues. Importantly, eCB system and gut microbiome, have been suggested to play a role in AD in both animal and human studies. Therefore, the microbiome gut-brain axis and the eCB system are potential common denominators in the AD physiopathology. Hence, the aim of this review is to provide a general overview on the role of both the eCB system and the microbiome gut-brain axis in AD and to suggest possible mechanisms that underlie the potential interplay of these two systems.
Keyphrases
- mild cognitive impairment
- cognitive decline
- endothelial cells
- gene expression
- white matter
- insulin resistance
- type diabetes
- mesenchymal stem cells
- early onset
- metabolic syndrome
- adipose tissue
- risk assessment
- magnetic resonance
- computed tomography
- climate change
- cognitive impairment
- intellectual disability
- cell therapy
- binding protein
- functional connectivity
- diffusion weighted imaging